Abstract: A formulation comprising liposomes, wherein the liposomes comprise, based on the liposome, 0.7 to 3.0 mol % of eritoran or a pharmaceutically acceptable salt thereof and 0.5 to 3.0 mol % of a PEGylated phospholipid.
Abstract: A shelf stable liposomal based oral rehydration formulation as a mixture has an improved beverage rehydration index performance. The liposomal rehydration salt formulation prevents severe dehydration, maintains body electrolytes and fluids in a human, and rehydrates a human. The formulation includes less than 0.4% phospholipids, having an average size less than 270 nm and an osmolality of about 200 mOsm/kg.
Abstract: The invention relates to the use of empty liposomes of defined lipid composition or mixtures of empty liposomes of defined lipid composition and to the use of other lipid bilayers or monolayers of defined lipid composition for the treatment and prevention of bacterial infections. It has been found that such liposomes, in particular a two- and a four-component mixture of liposomes comprising cholesterol and sphingomyelin, liposomes consisting of sphingomyelin, liposomes comprising sphingomyelin and phosphatidylcholine, and liposomes comprising cholesterol and phosphatidylcholine efficiently sequestrate a variety of toxins secreted by bacteria, thus preventing binding of bacterial toxins to target cells and toxin-induced lysis of the target cells. Injected intravenously, liposome mixtures prevented death of laboratory mice infected with lethal doses of Staphylococcus aureus or Streptococcus pneumoniae.
Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
August 4, 2020
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
Type:
Grant
Filed:
July 27, 2018
Date of Patent:
July 28, 2020
Assignee:
Celator Pharmaceuticals, Inc.
Inventors:
Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
Type:
Grant
Filed:
June 27, 2019
Date of Patent:
July 28, 2020
Assignee:
ZONEONE PHARMA, INC.
Inventors:
Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
Abstract: The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
July 21, 2020
Assignee:
Universität Heidelberg
Inventors:
Gert Fricker, Walter Mier, Frieder Helm, Philipp Uhl, Stephan Urban
Abstract: Embodiments of the present disclosure are related to multivesicular liposome formulations encapsulating zinc meloxicam complex microparticles. Methods of making the zinc meloxicam complex microparticles and administering the zinc meloxicam complex microparticles encapsulated in multivesicular liposome formulations and their use as medicaments are also provided.
Type:
Grant
Filed:
November 17, 2017
Date of Patent:
July 14, 2020
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Stephanie Kurz, Soroush Ardekani, Kathleen Dunne Albright Los, Katherine Stone, Ernest G. Schutt, Vladimir Kharitonov
Abstract: The disclosure describes a fusogenic liposome-coated porous silicon nanoparticles for high loading efficiency of anionic payloads (small molecules, dyes, nucleic acids), and for non-endocytic delivery of hydrophilic and lipophilic payloads by membrane fusion. The liposome coating can be further modified with targeting peptides or antibodies via covalent binding chemistry between the ligands and functionalized poly(ethylene glycol). The surface moieties can be transferred to the cellular membrane surface by fusogenic uptake. The composition of the disclosure can be applied in the treatment of diseases by delivering entrapped/encapsulated payloads.
Type:
Grant
Filed:
July 8, 2016
Date of Patent:
July 7, 2020
Assignee:
The Regents of the University of California
Inventors:
Michael J. Sailor, Byungji Kim, Jinyoung Kang
Abstract: A liposome formulation for delivery of Wnt signal pathway inhibitor is provided herein, which comprises lipid molecules and Wnt signal pathway inhibitor, wherein the liposome formulation is prepared through following steps: (1) providing an aqueous solution of the Wnt signal pathway inhibitor and providing an alcoholic solution of the lipid molecules, (2) mixing the aqueous solution of the Wnt signal pathway inhibitor and the alcoholic solution of the lipid molecules, (3) removing alcohol solvent to obtain the liposome formulation with Wnt signal pathway inhibitor encapsulated therein.
Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
Type:
Grant
Filed:
March 6, 2013
Date of Patent:
June 9, 2020
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
Abstract: Disclosed are a method of preparing liposomes using a mixed solvent of ethyl acetate and n-hexane for dissolving phospholipids, and a method of preparing a liposome frozen powder by putting a container including liposomes in a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, which methods are useful in food industry for no use of toxic chloroform. Disclosed also is adding the produced container including liposomes to a container filled with isopropyl alcohol, ethanol and/or methanol, followed by lyophilization, thus advantageously preventing deterioration in stability of liposome particles, as well as being almost completely returned to the original state.
Type:
Grant
Filed:
September 13, 2016
Date of Patent:
May 26, 2020
Assignee:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Pahn Shick Chang, Kyung Min Park, Eun Hye Yang, Ho Sup Jung
Abstract: The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.
Type:
Grant
Filed:
October 11, 2016
Date of Patent:
May 19, 2020
Assignee:
Universität Heidelberg
Inventors:
Philipp Uhl, Max Sauter, Uwe Haberkorn, Walter Mier, Gert Fricker
Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
April 14, 2020
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
Abstract: A composition comprising liposomes comprising a lipid layer defining an internal aqueous compartment, an anthracycline drug entrapped in the internal aqueous phase and mitomycin C prodrug incorporated into the lipid layer is described.
Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
Type:
Grant
Filed:
October 27, 2011
Date of Patent:
April 7, 2020
Assignee:
Pacira Pharmaceuticals, Inc.
Inventors:
Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
Abstract: CoQlO has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain.
Type:
Grant
Filed:
May 2, 2007
Date of Patent:
March 10, 2020
Inventors:
Sung Lan Hsia, Niven Rajin Narain, Indushekhar Persaud
Abstract: The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL).
Type:
Grant
Filed:
September 10, 2018
Date of Patent:
December 17, 2019
Assignee:
ZONEONE PHARMA, INC.
Inventors:
Mark E. Hayes, Charles O. Noble, Francis C. Szoka, Jr.
Abstract: The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids and/or not more than 10 mole percent of PEGylated lipids, the liposomes having a selected mean particle diameter in the size range of 40-200 nm and comprising a first corticosteroid in water soluble form, for the site-specific treatment of inflammatory disorders in humans, providing in human patients a fast, strong, and durable anti-inflammatory effect for at least 2 weeks at a dose of at most 5 mg/kg body weight of prednisolone or an equipotent dose corticosteroid other than prednisolone at a treatment frequency of at most once per two weeks.
Abstract: The instant invention is drawn to a hepatocyte targeted composition comprising insulin associated with a lipid construct comprising an amphipathic lipid and an extended amphipathic lipid that targets the construct to a receptor displayed by an hepatocyte. The composition can comprise a mixture of free insulin and insulin associated with the complex. The composition can be modified to protect insulin and the complex from degradation. The invention also includes methods for the manufacture of the composition and loading insulin into the composition and recycling various components of the composition. Methods of treating individuals inflicted with diabetes.